BioPharmSignal logoBioPharmSignal

Biotech News

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesFDA / regulatory

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies for trial enrollment and precisely evaluate treatment response BOSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing

Related news

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

XAIRBeyond Air2026-08-31 12:00 EST

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

HYPRHyperfine2026-08-20 12:15 EST

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

ICCMIceCure Medical2026-08-20 12:10 EST

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

ICCMIceCure Medical2026-07-29 12:25 EST

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

ADPTAdaptive Biotechnologies2026-09-01 20:05 EST

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

FEMYFEMASYS2026-08-19 13:00 EST

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

VTAKCatheter Precision2026-09-02 20:15 EST

Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean

TMCITreace Medical Concepts2026-09-17 21:16 EST

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

ADPTAdaptive Biotechnologies2026-09-01 20:05 EST

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

ADPTAdaptive Biotechnologies2026-06-30 12:30 EST

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

Stock data

Close
28.61 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States